C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium AcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an
C-Path’s Role in IHI Call 4: Enhancing Rare Disease Clinical Trials This memo outlines how C-Path can contribute as a key strategic regulatory partner to the Innovative Health Initiative’s (I
November 1, 2023-November 3, 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting Members of the CDRC team will join the CTOS at The Convention Centre Dublin in Ireland. The Connective Tissue Oncology Society...
October 18, 2023-October 22, 2023 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting Hosted from October 18-22 in Chicago, Ill., this meeting draws tropical medicine and global health professionals representing acad
October 11, 2023-October 15, 2023 IDWeek 2023 Hosted in Boston, Mass. from October 11-15, IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA
C-Path Welcomes ObvioHealth C-Path is proud to welcome ObvioHealth, a virtual research organization (VRO), as the newest member of its Electro
Postdoc Ruby Abrams Shares Professional Development Opportunities Provided by C-Path Critical Path Institute is dedicated to advancing careers in the medical development and regulatory science industries. We are hap
October 26, 2023-October 27, 2023 C-Path Hosts Its Scientific Breakthrough Summit 2023 The summit featured presentations and panel discussions with C-Path collaborators from industry, academia, global regulatory...
August 17, 2023 C-Path to Host a Scientific Breakthrough Summit Oct. 26-27 Addressing Unmet Regulatory Needs and Drug Development Opportunities through Collaborations in Type 1 Diabetes, Alpha-1 Antitrypsi
August 15, 2023 NORDs’ IAMRARE Registry Contributes Two New Datasets to C-Path’s RDCA-DAP, Boosting Rare Disease Research and Therapeutic Advancement TUCSON, Ariz., August 15, 2023 — Critical Path Institute (C-Path) announced today that the National Organization for Rare Disord